The mechanisms underlying cellular injury when human placental trophoblasts are exposed to hypoxia are unclear. Connective tissue growth factor (CTGF) mediates cell injury and fibrosis in diverse tissues. We hypothesized that hypoxia enhances the production of CTGF in primary term human trophoblasts. Using cultured term primary human trophoblasts as well as villous biopsies from term human placentas, we showed that CTGF protein is expressed in trophoblasts. When compared with cells cultured in standard conditions (FiO 2 ‫؍‬ 20%), exposure of primary human trophoblasts to low oxygen concentration (FiO 2 ‫؍‬ 8% or < 1%) enhanced the expression of CTGF mRNA in a time-dependent manner, with a significant increase in CTGF levels after 16 h (2.7 ؎ 0.7-fold; P < 0.01), reaching a maximum of 10.9 ؎ 3.2-fold at 72 h. Whereas exposure to hypoxia had no effect on cellular CTGF protein levels, secretion of CTGF to the medium was increased after 16 h in hypoxia and remained elevated through 72 h. The increase in cellular CTGF transcript levels and CTGF protein secretion was recapitulated by exposure of trophoblasts to agents that enhance the activity of hypoxia-inducible factor (HIF)1␣, including cobalt chloride or the proline hydroxylase inhibitor dimethyloxaloylglycine, and attenuated using the HIF1␣ inhibitor 2-methoxyestradiol. Although all TGF␤ isoforms stimulated the expression of CTGF in trophoblasts, only the expression of TGF␤1 mRNA was enhanced by hypoxia. We conclude that hypoxia increases cellular CTGF mRNA levels and CTGF protein secretion from cultured trophoblasts, likely in a HIF1␣-dependent manner. (Endocrinology 149:  2952-2958, 2008) 
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I NTACT PLACENTAL function is critical for normal growth and development of the mammalian embryo. The villus is the main functional unit within the human hemochorial placenta, and its surface trophoblast determines the transport of oxygen, nutrients, and waste products between fetal and maternal blood (reviewed in Refs. 1 and 2). The connective tissue of the villous core encases fetal vessels that permeate the villous tree. The trophoblast generates important endocrine and paracrine cues, which are implicated in the regulation of fetal growth and the maintenance of pregnancy. Injury to placental villous trophoblasts, attributed to hypoperfusion of the placental bed secondary to vascular insufficiency, is commonly associated with fetal growth restriction (FGR) (3, 4) . In its more severe form, this disease affects 3% of all pregnancies, and is associated with increased perinatal-neonatal mortality and morbidity, developmental delay, neurobehavioral dysfunction during childhood, and the metabolic syndrome during adult life (5, 6) . At the present time there is no treatment for FGR, except for optimization of the timing of delivery, intended to avert further injury.
Villous hypoxia is physiological in early fetoplacental development until late in the first trimester, when maternal blood begins to perfuse the intervillous space (7) (8) (9) . Trophoblast hypoxia becomes abnormal after the first trimester, when partial pressure of oxygen in the placental bed increases from 15-20 to 50 -60 mm Hg (7, 10) . Experiments using exposure of cultured trophoblasts to hypoxia, a common approach to study hypoxia-induced injury, suggest that the response of third trimester trophoblasts to hypoxia is different from that of first trimester trophoblasts. We and others have found that exposure of term primary human trophoblasts (PHTs) to hypoxic injury in vitro mitigates differentiation, and causes cell injury and apoptosis (11) (12) (13) (14) . Reduced placental size, villous surface area, and vascularity are frequent findings in pregnancies complicated by FGR attributed to placental injury (15) . Additional histological lesions include evidence of ischemia and infarct, fetal thrombotic vasculopathy, previllous fibrin or chronic villitis, which are postulated to contribute to trophoblast hypoxic injury (16) .
The molecular signals that regulate trophoblast response to injury are largely unknown. Using high-density oligonucleotide microarray screens, analyzed using correction to signal intensity and probe reliability (17), we previously showed a higher expression of connective tissue growth factor (CTGF) in cultured human trophoblasts that were exposed to hypoxia in vitro compared with standard culture conditions, as well as in placental villous samples from pregnancies complicated by FGR vs. matched controls (18) . CTGF is a heparin-binding 38-kDa member of the CTGF, Cyr61, and Nov (CCN) family of proteins that promote cell proliferation, cell migration, adhesion, angiogenesis, formation of extracellular matrix, fibrosis, and apoptosis, targeting primarily fibroblasts, endothelial cells, epithelial cells, chondrocytes, myocytes, mesangial cells, and neurons (reviewed in Refs. 19 -21) . During pregnancy CTGF (also known as CCN2 and Fisp12) is expressed in the uterine decidua, as well as in the trophectoderm and inner cell mass of the preimplantation murine embryo (22) . Later in development CTGF is expressed in the murine placenta, primarily in giant cells (E 14.5) (23) . Consistent with its high expression in embryonic vascular tissues and chondrocytes, CTGF deficient mice exhibit multiple defects in cartilage and matrix remodeling, chondrocyte proliferation, and angiogenesis within the bony growth plate, but no placental defects (24) . Overexpression of CTGF, targeted to chondrocytes, led to postnatal dwarfism and reduced bone mass (25) . Interestingly, another member of the CCN family, Cyr61 (CCN1, which has ϳ50% homology to CTGF), plays a key role in murine placental development, with Cyr61 mutant mice exhibiting increased midgestational lethality, reflecting abnormal nonsprouting angiogenesis in the chorion and allantois. These lesions result in defective chorioallantoic fusion and fetal undervascularization of the placenta without a primary defect in the labyrinthine trophoblast or spongiotrophoblast (26) . Because CTGF plays a central role in fibrosis and adaptation to injury in numerous organs, fibrin deposition and fibrosis are important lesions in injured villous trophoblasts in the human, and CTGF expression was up-regulated in our screen of hypoxic trophoblasts and FGR placentas, we hypothesized that hypoxia enhances the expression of CTGF in term human trophoblasts.
Materials and Methods

Trophoblast culture
The procurement of tissues for our studies was approved by the Institutional Review Board of Washington University School of Medicine. PHT cells were prepared from normal term placentas using the trypsin-deoxyribonuclease-dispase/Percoll method as described by Kliman et al., with previously published modifications (12, 27) . Cultures were plated at a density of 300,000 cells per cm 2 and maintained in DMEM (Sigma-Aldrich, St. Louis, MO) containing 10% FBS (SigmaAldrich), 20 mmol/liter HEPES (pH 7.4) (Sigma-Aldrich), penicillin (100 U/ml), streptomycin (100 g/ml), and Fungizone (0.25 g/ml; SigmaAldrich), all from Washington University tissue culture support center, at 37 C in a 5% carbon dioxide-air atmosphere. After 4 h, designed to allow cell attachment, the cells were washed three times in PBS, and the culture medium was replaced by medium containing FBS or serum free medium. This time point is defined as time zero for our experiments. When incubated for more than 24 h, the culture medium was changed every 24 h. Cells were cultured in either standard (FiO 2 ϭ 20%) or hypoxic growth conditions (FiO 2 Յ 1 or 8%). Cultures at the two hypoxic conditions were maintained concomitantly in two side-by-side incubators (Thermo Electron, Marietta, OH) that provided a defined hypoxic atmosphere of either less than 1 or 8% O 2 , where stated (5% CO 2 and complemented by N 2 , with added 10% H 2 to the Ͻ 1% O 2 ). The level of FiO 2 was continuously monitored using two separate oxygen sensors (KE-50; Figaro USA, Inc., Glenview, IL), which allowed a simultaneous recording of atmospheric conditions in each chamber (Ͻ0.1% change in FiO 2 ). Where indicated, the cultures were supplemented with dimethyloxaloylglycine (DMOG) (Cayman, Ann Arbor, MI), cobalt chloride (CoCl 2 ) (Sigma-Aldrich), TGF␤1, 2, and 3 (Sigma-Aldrich), 2-methoxy estradiol (Sigma-Aldrich), monensin sodium (Sigma-Aldrich), or recombinant CTGF (full-length from Promokine, Heidelberg, Germany, or the 98 aa C-terminal domain from Cell Sciences, Canton, MA). The concentrations are listed in each figure legend.
Immunohistochemistry and immunofluorescence
Placental biopsies from term uncomplicated pregnancies were collected immediately after delivery, fixed for 24 h in 10% neutral buffered formalin, and embedded in paraffin. Five-micron sections were deparaffinized in xylene and rehydrated in an ethanol gradient. Endogenous peroxidase activity was quenched using 3% H 2 O 2 in methanol for 30 min. After equilibrating for 5 min in distilled water, the samples were heated in a microwave at maximum power for 10 min. The slides were washed, blocked for 60 min with normal goat serum, and incubated for 2 h at room temperature in the absence or presence of affinity purified goat polyclonal anti-CTGF antibody (final 4 g/ml; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The antibody was also preincubated for 2 h at room temperature with CTGF specific blocking peptide (Santa Cruz Biotechnology) at a ratio of 5:1 blocking peptide to antibody. The mixture was then used for staining. After washes, the slides were incubated for 30 min with a biotinylated horse antigoat secondary antibody (Santa Cruz Biotechnology), followed by 30 min incubation with avidin/biotin-horseradish peroxidase complex (Vector Laboratories, Burlingame, CA) and 3-min incubation with diaminobenzidine (Zymed Laboratories, Inc., San Francisco, CA). The slides were rinsed and counterstained with Mayer's hematoxylin (Sigma-Aldrich), dehydrated in ethanol, cleared with xylene, and mounted with glass coverslips using Histomount (Zymed Laboratories).
For immunofluorescence of CTGF, we cultured primary trophoblasts for 72 h and stained the cells for desmosomes using mouse antidesmosome antibody as we previously described (12) . For fluorescent detection of CTGF, we incubated the cells with rabbit anti-CTGF antibody (final 2 g/ml; Santa Cruz Biotechnology), diluted in blocking buffer for 1 h. After washes, the cells were incubated with a cocktail of Alexa Fluor 555-linked donkey antirabbit IgG (final 8 g/ml, Alexa Fluor 555; Molecular Probes/Invitrogen Corp., Carlsbad, CA) and Alexa Fluor 488-linked donkey antimouse IgG (final 8 g/ml; Molecular Probes) for an additional 30 min at room temperature. After washing, the cells were stained with 1:250 TO-PRO-3 iodide (Invitrogen) for 15 min, and then mounted with GelMount (Biomeda, Foster City, CA) and viewed using a Nikon E800 fluorescence confocal microscope (Nikon Corp., Tokyo, Japan). A syncytium was defined as three or more nuclei in the same cytoplasm without intervening surface desmosomal membrane staining.
Western immunoblotting and concentration of medium CTGF
Trophoblasts were lysed with cold lysis buffer (1% Nonidet P-40, 0.5% deoxycholate, and 0.1% sodium dodecyl sulfate in PBS) containing a protease inhibitor cocktail (Sigma-Aldrich). The plates were scraped, and the lysate was sonicated on ice, centrifuged, and protein concentration was determined. For detection of hypoxia-inducible factor (HIF) 1␣, the extraction was performed in 2ϫ sample buffer instead of the lysis buffer, and without sonication. The proteins (20 -30 g/lane) were resolved using either 10% (CTGF) or 6% (HIF1␣) SDS-PAGE at 80 V for 3 h, and then transferred overnight to polyvinylidene difluoride membranes (Immobilon-P; Millipore, Bedford, MA) at 4 C, 150 mA. After blocking for 1 h in 5% nonfat dry milk in Tris-buffered saline (with 0.05% Tween 20), the blots were incubated with an affinity purified rabbit polyclonal anti-CTGF antibody (final 0.2 g/ml; Santa Cruz Biotechnology), mouse monoclonal anti-HIF1␣ (final 1.3 g/ml, NB-100 -105; Novus Biologicals, Inc., Littleton, CO), or goat polyclonal antiactin (final 0.2 g/ml; Santa Cruz Biotechnology) for 2 h, followed by the appropriate horseradish peroxidase-linked secondary IgG antibodies (all from Santa Cruz Biotechnology) for 1 h at room temperature, and processed for luminescence using the Amersham Pharmacia ECL kit (GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Chemiluminescence was densitometrically analyzed using Epichemi-3 software (UVP BioImaging System; Ultraviolet Products, Upland, CA).
For detection of CTGF in the culture medium, we used a disposable ultrafiltration centrifugal device for medium concentration (iCON Concentrator, 7 ml/20 K; Pierce, Rockford, IL), which has a molecular weight cutoff of 20,000. Serum free medium samples (5 ml) were collected from trophoblasts and placed in the upper sample chamber of concentrator tube. The tube was centrifuged at 1600 ϫ g for 20 min at 4 C using a swinging-bucket rotor. The concentrated sample (50 -70 l) was collected from the upper chamber and added to sample buffer after adjustment for protein concentration of the plated cells. CTGF was detected using immunoblotting as described previously.
Quantitative RT-PCR (RT-qPCR)
RNA was purified from primary trophoblasts using TriReagent (Molecular Research Center, Cincinnati, OH) and processed for RT as we previously described (28) . For RT-qPCR we used 2 g cDNA and 300 nm of each forward and reverse gene-specific primer as specified in Table  1 , with specificity confirmed using BLAST. The PCR mixture (25 l), prepared as we previously described (28) (29) . Reactions and dissociation curves were analyzed as we previously described (28) using the 2 Ϫ⌬⌬CT method (30).
Statistics
Each experiment was performed in duplicate and repeated as detailed in each legend. Results are depicted by a representative experiment, and analyzed on the pooled data using the Primer of Biostatistics software package (McGraw-Hill, Inc., New York, NY) by either Kruskal-Wallis, one-way ANOVA with post hoc Dunnett's test, or Mann-Whitney rank sum test, where appropriate. A value of P Ͻ 0.05 was determined significant.
Results
We initially determined the expression of CTGF protein in villi derived from human third trimester placentas, obtained after normal pregnancy and delivery. As shown in Fig. 1 , A-C), we detected CTGF protein primarily in the trophoblast bilayer circumscribing the placental villi. CTGF immunoreactivity was also detected in cytotrophoblasts (Fig. 1D) , endothelial cells (Fig. 1E) , and, to a lesser degree, in some of the adjacent connective tissue cells within the villous core. For positive control we used a cross section of umbilical artery muscularis layer (Fig. 1F) . The expression of CTGF protein in cultured trophoblasts was comparable in syncytia and in mononucleated cytotrophoblasts (Fig. 1G) . We obtained a similar result using trophoblasts cultured for 72 h in either DMEM, which supports cytotrophoblasts differentiation into syncytium, or Ham's-Waymouth medium, which hinders differentiation (31) (Fig. 1H) .
To explore the influence of hypoxia on CTGF expression, we initially determined the time course of CTGF mRNA levels in PHT cells. Whereas the expression of CTGF transcript was gradually reduced in cells cultured in standard conditions for 72 h, hypoxia mitigated this reduction, resulting in a relative increase in the levels of CTGF mRNA after 24-h hypoxia ( Fig. 2A) . This effect was dependent on oxygen concentration, with a significant effect when FiO 2 was reduced to less than or equal to 1%, but not 8% (Fig. 2B) . We next determined if the hypoxia-induced increase in CTGF transcript resulted in higher levels of cellular CTGF protein.
As shown in Fig. 3A , we found that cellular CTGF levels were unchanged when the cells were cultured in hypoxia up to 72 h. Because FBS contains CTGF and other growth factors that might have influenced cellular CTGF levels, we repeated this experiment in serum free conditions and found similar results (Fig. 3B) , indicating that hypoxia does not change the steady-state level of intracellular CTGF protein in trophoblasts. Importantly, we found that hypoxia led to increased CTGF protein levels in serum free tissue culture medium. This increase was observed as early as 24 h in hypoxia and was sustained for 72 h in culture (Fig. 3C) . The sodiumproton ionophore monensin, which disrupts protein secretion by neutralizing the intracellular acidic compartment of lysosomes and the trans-Golgi apparatus (32) , attenuated the hypoxia-stimulated CTGF secretion (Fig. 3D) . Together, our findings indicate that hypoxia enhances the expression of CTGF transcripts and the secretion of CTGF protein without altering intercellular CTGF protein levels in term PHT cells. Because CTGF harbors HIF1␣-binding hypoxia response elements upstream of CTGF coding sequences (33), we surmised that HIF1␣ regulates CTGF expression in PHT cells. We first determined that the hypoxia mimetic chemicals CoCl 2 or DMOG, which stabilize HIF1␣ levels by inhibiting prolyl hydroxylation and subsequent ubiquitination, enhance CTGF expression. As shown in Fig. 4 , A-C, both CoCl 2 and DMOG enhanced the expression of CTGF transcript as well as secreted CTGF protein, but not cellular CTGF. As a control, we demonstrated that both chemicals also enhance the expression of HIF1␣ in primary trophoblasts (Fig. 4D) . Consistent with these observations, we found that the expression of HIF1␣ is up-regulated in hypoxic trophoblast, and that the antiangiogenic chemical 2-methoxy-estradiol (2meE 2 ) that reduces HIF1␣ levels in other cell systems (34) indeed diminished HIF1␣ expression in trophoblasts (Fig.  4E) . When we exposed PHT cells to hypoxia, we found that 2meE 2 mitigated the up-regulation of CTGF expression [with vascular endothelial growth factor (VEGF) as a positive control, Fig. 4F ]. Because TGF␤ isoforms are up-regulated in hypoxic trophoblasts (35) (36) (37) (38) and were implicated in expression of CTGF, we examined the influence of TGF␤1, 2, or 3 on the expression of CTGF. As shown in Fig. 5 , all three TGF␤ isoforms enhanced the expression of CTGF in PHTs. Importantly, when we analyzed the time course of hypoxia-induced TGF␤ expression in trophoblasts, we found that only   FIG. 2 . Hypoxia regulates the expression of CTGF mRNA in human trophoblasts. PHT cells from term normal placentas were cultured in standard culture conditions (FiO 2 ϭ 20%) or in two conditions of reduced FiO 2 , 8% or less than or equal to 1%. CTGF transcript expression was determined using RT-qPCR as described in Materials and Methods. A, Time course for the effect of FiO 2 less than or equal to 1%, depicting the fold change in CTGF expression between the two conditions (*, P Ͻ 0.05, Mann-Whitney U test; n ϭ 5). B, The influence of oxygen concentration on the expression of CTGF transcript (*P Ͻ 0.05, Kruskal-Wallis one-way ANOVA with post hoc Dunnett's test; n ϭ 3).
FIG. 3.
Hypoxia increases the secretion of CTGF from human trophoblasts. PHT cells from term normal placentas were cultured in standard culture conditions (Std) (FiO 2 ϭ 20%) or in hypoxia (Hpx) (FiO 2 Յ 1%, n ϭ 4). A and B, Cellular CTGF protein expression in cells cultured in serum-containing (A) or serum free (B) medium determined using Western immunoblotting as described in Materials and Methods. C, CTGF protein levels in serum free culture medium. D, The effect of monensin on hypoxia-stimulated CTGF secretion from trophoblasts cultured for 48 h in standard conditions or hypoxia (FiO 2 Յ 1%) in serum free medium in the presence or absence of monensin (*P Ͻ 0.05, ANOVA, n ϭ 3, quantified as shown in the panel below the gel).
the induction of TGF␤1 was consistent with the up-regulation of CTGF (Fig. 5B, upper panel) . Moreover, the hypoxiainduced increase in TGF␤1 transcript temporally preceded that induction of CTGF transcript (Fig. 5B, lower panel) . Together, our results buttress our findings regarding the influence of hypoxia on CTGF expression in human trophoblasts, and implicate HIF1␣ and TGF␤1 in the regulation of CTGF in PHT cells.
Finally, we sought to determine whether CTGF influences the expression of mediators of fibrosis or hypoxia-related transcripts within PHT cells. The addition of recombinant full-length CTGF (0.125-0.25 g/kg) or the 98 aa C-terminal domain of CTGF (1-4 g/kg) (39) to cultured term PHT cells, in the absence or presence of serum for 24 -48 h, had no effect on cell morphology or on the expression of mRNA for VEGF, N-Myc down-regulated gene 1, erythropoietin, transferring receptor, matrix metalloproteinases (MMPs) MMP2 and MMP3, and their tissue inhibitors of metalloproteinases 1-4, yet CTGF increased the level of transcripts for MMP3 and tissue inhibitor of metalloproteinase 2 in the IMR-90 fibroblast line, used as a control (data not shown).
Discussion
We analyzed the expression of CTGF in human third trimester villous tissue, and found that CTGF protein was expressed primarily in trophoblasts, villous endothelial cells, and, to a lesser degree, in some of the adjacent connective tissue cells within the villous core. The uniform expression pattern of CTGF protein throughout the culture period in conditions that either support or hinder trophoblast differentiation (12) bolsters the finding that CTGF is expressed in both differentiated syncytiotrophoblasts and undifferentiated cytotrophoblasts. Importantly, whereas CTGF mRNA levels decrease as trophoblasts differentiate in culture, hypoxia reverses the decline in CTGF, resulting in a higher level of CTGF mRNA in cells cultured in FiO 2 less than or equal to 1%, compared with cells cultured in FiO 2 of either 20 or 8%. Interestingly, Higgins et al. (33) found that primary renal tubular epithelial cells exhibited an increase in CTGF mRNA in response to hypoxia, without an initial decline as we observed in human trophoplasts. This difference in the in- fluence of hypoxia on CTGF may reflect the different cell types used in these studies and a difference in the experimental time course between the two cell systems.
CTGF is secreted after processing in the Golgi (40, 41) . We found that although the level of intracellular CTGF protein remained stable in hypoxic trophoblasts, medium levels of CTGF were increased by hypoxia. This increase was attenuated in a concentration-dependent manner by monensin, which inhibits protein transport at the trans-Golgi (32, 42) . These findings suggest that in addition to its effect on increasing CTGF mRNA, hypoxia enhances the secretion of CTGF from trophoblasts. However, monensin does not completely block the increase in protein secretion, implying that other mechanisms contribute to the increase in extracellular CTGF protein levels.
Several observations also support a role for HIF1␣ in hypoxia-dependent stimulation of CTGF expression and secretion: 1) HIF1␣ expression is enhanced concomitantly with CTGF transcript in PHT cells; 2) the hypoxia-mimetics CoCl 2 and DMOG, which diminish HIF1␣ degradation, recapitulate the effect of hypoxia on CTGF mRNA expression and CTGF protein secretion; and 3) 2meE 2 , which degrades HIF1␣ protein, attenuates the hypoxia-induced increase in CTGF expression. Whereas hypoxia alters the secretion of CTGF from several cell types (33, (43) (44) (45) (46) , this is the first description of CTGF protein expression and secretion from human trophoblasts in response to hypoxia. CTGF is regulated by hypoxia via at least two distinct mechanisms: 1) binding of HIF1␣ to two hypoxia responsive elements (Ϫ3745/3741 and Ϫ1558/1554 sites) in the 5Ј-sequences of the murine CTGF gene and enhancing promoter activity in murine primary tubular epithelial cells (33); and 2) regulation of CTGF mRNA via the cis-acting element of structure-anchored repression, located within the 3Јuntranslated region of CTGF gene (44) . Interestingly, CTGF has also been implicated in the pathogenesis of hyperoxia-induced lung fibrosis in a rat model (47) , as well as fibrosis in other, nonplacental tissues. Several modulators of fibrosis (e.g. fibronectin, MMPs) are known targets for CTGF (48 -56) . The exact cellular and molecular targets for CTGF action within the placenta, and the potential role of CTGF in placental fibrosis, remain unknown. Moreover, the lack of effect of CTGF on extracellular matrix-related transcripts within trophoblasts suggests that CTGF, secreted from injured trophoblasts, may influence other villous cell types. Alternatively, CTGF may function as an adaptor molecule that modulates the action of other ligands, such as TGF␤, epidermal growth factor, and VEGF, on membrane receptors (19, (57) (58) (59) .
Our data regarding the effect of TGF␤ on the expression of CTGF is consistent with previous observations, which demonstrated that TGF␤ is a potent stimulus of CTGF expression and regulates CTGF in a cell-dependent manner (56, 58, 60, 61) . Consistent with these data, silencing of CTGF attenuates some of the pro-fibrosis effects of TGF␤ (62) . Because CTGF mimics many of the actions of TGF␤, and TGF␤ signaling commonly transduces the impact of hypoxia to cells, including trophoblasts, it is tempting to assume that TGF␤ mediates the influence of hypoxia on CTGF (37, 38) . In contrast, up-regulation of CTGF during adaptation to injury, including hypoxia, may be independent of TGF␤ or small mothers against decapentaplegic (SMAD) protein signaling (33, 63) . It remains to be established if TGF␤, hypoxia, and other signaling pathways cooperatively regulate CTGF when trophoblasts are exposed to cellular injury.
